# Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia

> **NCT02277847** · PHASE4 · UNKNOWN · sponsor: **Guangdong Provincial People's Hospital** · enrollment: 400 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Idarubicin(8mg/m2) and cytosine arabinoside
- **DRUG:** Idarubicin(10mg/m2), cytosine arabinoside

## Key facts

- **NCT ID:** NCT02277847
- **Lead sponsor:** Guangdong Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-03
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2014-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02277847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02277847, "Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02277847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*